Nanobiotix Finalizes $100M Global Offering with Full Over-Allotment Exercise

summarizeSummary

Nanobiotix announced the full exercise of its offering's over-allotment option, bringing the total capital raised to $100 million and extending its cash runway into 2029.

check_boxKey Events

• Global Offering Finalized

  Underwriters fully exercised their over-allotment option, bringing the total gross proceeds from the global offering to approximately $100 million. This finalizes the offering launched on May 20, 2026, and priced on May 21, 2026.

• Extended Cash Runway

  The company expects the net proceeds, combined with existing cash and cash equivalents, to meet its working capital requirements for operations into 2029.

• Funding for Key Programs

  Proceeds will primarily advance the Nanoprimer and other platforms (50-60%), with a portion for JNJ-1900 development (less than 10%) and general corporate purposes (30-40%).

• Offering Price

  The offering price was $38.98 per American Depositary Share (ADS), representing a modest discount to the current market price.

auto_awesomeAnalysis

This filing confirms the successful completion of Nanobiotix's global offering, with underwriters fully exercising their over-allotment option. The total capital raised of approximately $100 million significantly extends the company's cash runway into 2029, providing crucial funding for its Nanoprimer and other platform developments. This follows the pricing announcement on May 21, 2026, and indicates strong investor demand for the offering.